![Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire](https://mms.businesswire.com/media/20210107005469/en/850619/4/logoHD.jpg)
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting
![Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire](https://mms.businesswire.com/media/20210831005934/en/902034/23/MedinCell_LOGO.jpg)
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire
Clinical Trials Arena on Twitter: "Schizophrenia drug landscape: a stagnant field on the cusp of change? @WillNewton19 talks to experts about Sunovion's ulotaront, Minerva's roluperidone, and Teva and MedinCell's extended-release risperidone $SEPR $
![Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market - Clinical Trials Arena Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market - Clinical Trials Arena](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/11/Glenmark-1038x778.jpg)
Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market - Clinical Trials Arena
![Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021 Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021](https://pharma.nridigital.com/pharma/pharma_feb21/teva_medincell_lai_schizophrenia/1118760/__screenshot.jpg)
Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021
![Sezepine Forte Risperidone Trihexyphenidyl Tablets, Vega Biotec Pvt Ltd, 5x4x10, Rs 1120/box | ID: 23427778548 Sezepine Forte Risperidone Trihexyphenidyl Tablets, Vega Biotec Pvt Ltd, 5x4x10, Rs 1120/box | ID: 23427778548](https://5.imimg.com/data5/SELLER/Default/2021/5/JG/WQ/HR/3184985/sezepineforte-500x500.jpg)